LONDON–(BUSINESS WIRE)–IMU Biosciences (‘IMU or the ‘Company’), a biotechnology company using its High Definition Immunology™ platform to better understand the immune system and drive a shift in how we understand, diagnose, and treat disease, has today announced a new collaboration with UK Biobank to generate large-scale multi-omic immune profiling data from 80,000 blood samples collected from UK Biobank participants. The project will use IMU’s HD Immunology™ platform in conjunction with Wate

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.